Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BTI320 for Glycemic Control in Type 2 Diabetes
NCT03655535Phase 2Completed
- Sponsor
- Boston Therapeutics, Inc.
- Start
- Sep 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BTI320 in type 2 diabetes mellitus (T2DM), sponsored by Boston Therapeutics, Inc.. Started Sep 2018; status: completed.
02
Drugs
BTI320
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03655535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03655535.